MedPath
Found 12 clinical trials|View Analysis
Sort by:

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Phase 1
Not yet recruiting
Conditions
Obesity
Interventions
Drug: Survodutide
Drug: Semaglutide
First Posted Date
2024-12-20
Last Posted Date
2024-12-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
60
Registration Number
NCT06745284
Locations
🇺🇸

AdventHealth, Orlando, Florida, United States

🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

LIVERAGEâ„¢: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase 3
Recruiting
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Interventions
Drug: Survodutide
Drug: Placebo
First Posted Date
2024-10-09
Last Posted Date
2024-12-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1800
Registration Number
NCT06632444
Locations
🇺🇸

The Institute for Liver Health, LLC, Tucson, Arizona, United States

🇺🇸

Scottsdale Clinical Trials, Scottsdale, Arizona, United States

🇺🇸

Adobe Clinical Research, LLC, Tucson, Arizona, United States

and more 125 locations

LIVERAGEâ„¢ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase 3
Recruiting
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Drug: Survodutide
Drug: Placebo matching survodutide
First Posted Date
2024-10-09
Last Posted Date
2024-12-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1590
Registration Number
NCT06632457
Locations
🇺🇸

Scottsdale Clinical Trials, Scottsdale, Arizona, United States

🇺🇸

Synergy Healthcare, Brandon, Florida, United States

🇺🇸

Optimus U Corporation-Miami-69452, Miami, Florida, United States

and more 6 locations

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase 1
Active, not recruiting
Conditions
Obesity
Overweight
Interventions
First Posted Date
2024-08-21
Last Posted Date
2024-12-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT06564441
Locations
🇧🇪

SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase 1
Active, not recruiting
Conditions
Overweight
Obesity
Interventions
Drug: survodutide
First Posted Date
2024-07-09
Last Posted Date
2025-01-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT06492135
Locations
🇨🇳

Shanghai Central Hospital of Xuhui District, Shanghai, China

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

Phase 3
Recruiting
Conditions
Obesity
Non-Alcoholic SteatoHepatitis (NASH)
Interventions
Drug: Placebo
Drug: Survodutide
First Posted Date
2024-03-13
Last Posted Date
2024-12-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
160
Registration Number
NCT06309992
Locations
🇺🇸

Excel Medical Clinical Trials, Boca Raton, Florida, United States

🇺🇸

Bruce A. Segal, MD, PA, Delray Beach, Florida, United States

🇺🇸

Velocity Clinical Research-Gardena-69773, Gardena, California, United States

and more 21 locations

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Overweight
Interventions
Drug: survodutide
Drug: Placebo matching BI 456906
First Posted Date
2024-01-22
Last Posted Date
2024-12-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
307
Registration Number
NCT06214741
Locations
🇨🇳

Beijing Chao-Yang Hospital, Beijing, China

🇨🇳

Peking University People's Hospital, Beijing, China

🇨🇳

Beijing Pinggu Hospital, Beijing, China

and more 27 locations

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Survodutide
Drug: Placebo matching survodutide
First Posted Date
2023-12-19
Last Posted Date
2025-01-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
274
Registration Number
NCT06176365
Locations
🇯🇵

Shimamura Kinen Hospital, Tokyo, Nerima-ku, Japan

🇯🇵

Chiba University Hospital, Chiba, Chiba, Japan

🇯🇵

Hosokawa Surgery Clinic, Aichi, Nagoya, Japan

and more 25 locations

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZEâ„¢ - CVOT)

Phase 3
Recruiting
Conditions
Obesity
Interventions
Drug: Placebo
Drug: survodutide
First Posted Date
2023-10-11
Last Posted Date
2024-12-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4935
Registration Number
NCT06077864
Locations
🇺🇸

Verus Clinical Research Corporation, Miami, Florida, United States

🇺🇸

IMA Clinical Research San Antonio, San Antonio, Texas, United States

🇺🇸

Synexus Clinical Research, Salt Lake City, Utah, United States

and more 571 locations

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Diabetes Mellitus, Type 2
Interventions
Drug: Survodutide
Drug: Placebo
First Posted Date
2023-10-04
Last Posted Date
2024-12-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
755
Registration Number
NCT06066528
Locations
🇺🇸

EmVenio Research-Atlanta-69582, Phoenix, Arizona, United States

🇺🇸

Alliance for Multispecialty Research-Coral Gables-68872, Coral Gables, Florida, United States

🇺🇸

East Coast Institute for Research, LLC-Jacksonville-55146, Jacksonville, Florida, United States

and more 140 locations
© Copyright 2025. All Rights Reserved by MedPath